1. Home
  2. ALX vs DMRA Comparison

ALX vs DMRA Comparison

Compare ALX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexander's Inc.

ALX

Alexander's Inc.

HOLD

Current Price

$261.77

Market Cap

1.3B

Sector

Real Estate

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$28.56

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALX
DMRA
Founded
1928
2011
Country
United States
United States
Employees
N/A
7
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
ALX
DMRA
Price
$261.77
$28.56
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$43.00
AVG Volume (30 Days)
15.7K
466.5K
Earning Date
05-04-2026
05-11-2026
Dividend Yield
7.20%
N/A
EPS Growth
N/A
N/A
EPS
0.91
N/A
Revenue
$213,183,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$280.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$201.28
$16.50
52 Week High
$289.43
$34.89

Technical Indicators

Market Signals
Indicator
ALX
DMRA
Relative Strength Index (RSI) 46.95 51.33
Support Level $229.61 $22.71
Resistance Level $271.02 $34.89
Average True Range (ATR) 7.37 2.13
MACD -2.61 -0.44
Stochastic Oscillator 37.90 9.51

Price Performance

Historical Comparison
ALX
DMRA

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: